Safety Study Involving Oxaliplatin With Docetaxel for Recurrent Ovarian,Primary Peritoneal, and Fallopian Tube Cancer
Status:
Completed
Trial end date:
2013-10-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the safest and maximum tolerated dosing regimens
for intraperitoneal oxaliplatin with intravenous docetaxel and intravenous oxaliplatin with
intraperitoneal docetaxel for recurrent ovarian, primary peritoneal, or fallopian tube
cancer.